ReceptoPharm // Drug Development // Published Research

Drug Development

» Overview

» Research Platform

» R&D Pipeline

» Published Research

» Licensing

Drug Development

ReceptoPharm is developing proprietary therapeutic protein products for the treatment of neurological, viral and and autoimmune disorders.

» Learn More

CRO Services

ReceptoPharm offers a full range of contract research services catering to small and start-up biotech companies.

» Learn More

Published Research

Cobratoxin inhibits pain-evoked discharge of neurons in thalamic parafascicular nucleus in rats: Involvement of cholinergic and serotonergic systems

Toxicon
Volume 54/ Issue 4 (15 September 2009)

Download PDF

Alpha cobratoxin as a Possible Therapy for Multiple Sclerosis: A Review of the Literature leading to Its Development for This Application

Critical Reviews™ in Immunology
Volume 27/ Issue 4 2007

Download PDF

Analgesic effects of receptin, a chemically modified cobratoxin from Thailand cobra venom

Neuroscience Bulletin
September 2006

Download PDF

Amelioration of acute and relapsing stages of the Experimental Allergic Encephalomyelitis by Cobra Toxins

Biomedical Sciences Instrumentation
June 2006

Download PDF

A long-form a-neurotoxin from cobra venom produces potent opioid-independent analgesia

Acta Pharmacologica Sinica
April 2006

Download PDF

A short-chain a-neurotoxin from Naja naja atra produces potent cholinergic-dependent analgesia

Neuroscience Bulletin
March 2006

Download PDF